InvestorsHub Logo
Followers 0
Posts 11
Boards Moderated 0
Alias Born 10/31/2014

Re: None

Monday, 04/20/2015 11:26:15 AM

Monday, April 20, 2015 11:26:15 AM

Post# of 146238
Did I just read, 'who would buy a product that reduces herpes (chickenpox, genital herpes, cold sores,shingles etc etc) flair ups by 90 percent and prevents scabs and scarring? Well since Zovirax has sales of 29.2 million a quarter with a 70 percent profit margin and is only 2 percent as effective as the NNVC Herpecide findings, i'm thinking Everyone!

The whole point of a topical treatment for people who have the virus (which is 50 percent of the human population in which 30 percent are affected by the breakouts) is to apply an ointment on the initial 'itchy feeling' you get when the flair ups occur. The breakouts are the problem! There is ample warning of the breakouts and applying the topical ointment would prevent the spread and stop the breakout.

This announcement will certainly catch the attention of current Pharmaceutical ointment manufacturers. All NNVC will need to do is license the drug which will generate 100's of millions in revenue. This will certainly be the first, easiest and fastest way to generate revenue.

How anyone could spin this into a negative is (fill in the blank)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NNVC News